Abstract：
A male patient in his early 30s was diagnosed with bronchial asthma 3 years previously. He responded well to inhaled corticosteroids and long-acting beta-agonists. Approximately 18 months from the onset, the patient reported worsening symptoms. These symptoms included severe functional limitations, requiring frequent exposure to high-dose prednisolone. Mepolizumab was added to the treatment, leading to optimal control of bronchial asthma. Despite receiving seven doses of mepolizumab at monthly intervals, the patient developed cervical and postauricular lymphadenopathy and subcutaneous swelling of soft tissue. A cervical lymph node biopsy confirmed the diagnosis of Kimura disease. Following treatment with oral glucocorticoids and methotrexate, the patient experienced a complete resolution of symptoms. He has been in remission and off oral prednisolone for the last 13 months. In this case, we highlight the development of Kimura disease in a patient undergoing mepolizumab treatment.
摘要：
3年前，一名30多岁的男性患者被诊断出患有支气管哮喘。他对吸入皮质类固醇和长效β受体激动剂反应良好。发病大约18个月后，患者报告症状恶化。这些症状包括严重的功能限制，需要频繁接触高剂量泼尼松龙。Mepolizumab被添加到治疗中，导致支气管哮喘的最佳控制。尽管每月服用7剂美泊利单抗，患者出现颈部和耳后淋巴结病和皮下软组织肿胀。颈淋巴结活检证实了Kimura病的诊断。口服糖皮质激素和甲氨蝶呤治疗后，患者症状完全缓解。在过去的13个月中，他一直在缓解和口服泼尼松龙。在这种情况下,我们重点介绍了接受mepolizumab治疗的患者发生Kimura病的过程.
